WA-KYMETA
18.3.2024 13:01:27 CET | Business Wire | Press release
World-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com), announced today at SATELLITE 2024 that the Osprey u8 HGL, a hybrid geostationary/low Earth orbit (GEO/LEO/LTE) terminal purpose-built for military users, is shipping out of their facility in Woodinville, Washington. This marks the first commercially available multi-orbit terminal and the first multi-orbit terminal on Eutelsat OneWeb’s LEO network. Kymeta announced the official launch in October last year and is fulfilling a backlog of orders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318848741/en/
Kymeta - The Future of Military SATCOM is now. On the move GEO-LEO-LTE from one single terminal - Osprey u8 HGL (Graphic: Business Wire)
In February, the Kymeta team demonstrated in the field the capabilities of the new Osprey u8 HGL delivering resilient, auto-PACE ready communications for the armed forces to meet the demands of challenging and rugged military environments. The multi-orbit, multi-network capabilities of the Osprey u8 HGL terminal will offer even greater availability, while being durable, low power consuming, having low visibility, and easy to use.
The Osprey u8 HGL includes a field swappable modem cartridge and a OneWeb modem to enable connectivity with the Eutelsat OneWeb LEO network. At launch an iDirect 950mp cartridge is available enabling TRANSEC services over GEO. Other cartridge configurations will be available soon enabling end users to customize their terminal configuration based on their mission needs.
Initial feedback was overwhelmingly positive, with one military member stating: “This is everything we’ve been looking for in a terminal, form function and features. The LEO to GEO switching far exceeded our expectations. It’s amazing that Kymeta is already delivering on the community’s urgent need for multi-orbit SATCOM.”
Others in attendance at Army field demonstrations commented, “I cannot wait to get started with these!” and “Wow! It tracks satellites over some very difficult terrain.”
“The Kymeta Osprey HGL has a unique capability to address government requirements in support of government PACE plans,” said Ian Canning, Chief Operating Officer, OneWeb Technologies. “The Osprey supports multi-network/orbit requirements through the concurrent LTE/satellite configuration with the added benefit of now being able to add OneWeb LEO capabilities.”
Jon Osler, Senior Vice President Global Sales and Services of Kymeta, commented: “In the contemporary military landscape, mobile connectivity has become indispensable for achieving success. Unlike any other sector, the military relies heavily on dependable, adaptable, and resilient on-the-go communication systems to fulfill its operational and training needs. We take pride in our longstanding partnership with the military, delivering cutting-edge solutions that meet and exceed expectations.”
This milestone further establishes Kymeta as the leader in the multi-X revolution. Attendees of SATELLITE 2024 in Washington, DC, March 18– 20 are encouraged to visit Kymeta’s meeting room 156 to see the Osprey u8 HGL in person and to speak with a member of the Kymeta team.
About Kymeta
Kymeta is the industry leader in flat panel satellite antennas, providing purpose-built solutions across a variety of enterprise and military applications and unlocking the commercial value of space to address the vast, unmet demand for ubiquitous broadband and truly mobile connectivity for customers around the world. Its innovative metasurface technology, coupled with a software-first approach, delivers the first commercially available, metamaterial-based and electronically steered flat panel satellite antenna. Kymeta’s low-cost, low power and high throughput solutions make it easy to connect on the move or while stationary – for any vehicle, vessel, aircraft, or fixed platform – enabling industries on earth to transform their operations by harnessing capacity in space.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318848741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom